EP0316776A2 - Monoclonal antibodies to anthracyclines - Google Patents
Monoclonal antibodies to anthracyclines Download PDFInfo
- Publication number
- EP0316776A2 EP0316776A2 EP88118771A EP88118771A EP0316776A2 EP 0316776 A2 EP0316776 A2 EP 0316776A2 EP 88118771 A EP88118771 A EP 88118771A EP 88118771 A EP88118771 A EP 88118771A EP 0316776 A2 EP0316776 A2 EP 0316776A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- monoclonal antibodies
- hybridomas
- carrier
- anthracyclines
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title claims description 9
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 3
- 230000003393 splenic effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 17
- 229960004679 doxorubicin Drugs 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QLNSPJMIYWEWNF-UHFFFAOYSA-N CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C QLNSPJMIYWEWNF-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention concerns hybridomas secreting monoclonal antibodies able to selectively bind to doxorubicin as well as to analogues and derivatives thereof.
- the invention concerns also the monoclonal antibodies secreted by said hybridomas able to selectively bind to doxorubicin.
- a further object of the invention is provided by diagnostic and/or therapeutic applications of the above cited monoclonal antibodies.
- Said antibodies are secreted by hybrid cells, deriving from the fusion of immune lymphocytes against the desired antigen with a line of myeloma cells having specific characteristics, in order to impart immortality to the antibody producing lymphocyte cells.
- the hybrid cells deriving from said fusion exhibit both the properties of lymphocytes of producing antibodies of a given specificity and the immortal character of the parental tumor cell.
- the hybrid cells are then cloned so as to obtain clones each deriving from a single cell, producing only one kind of antibody.
- the selected clone secreting the desired antibody may be kept viable undefinitely both by transplanting it in vivo in athymic mice and cultivating it in vitro .
- Doxorubicin, daunomycin and the semi-synthetic derivative epirubicin are drugs whose clinical effectiveness is widely known, belonging to the chemical class of anthracyclines; in addition to the above cited parent compounds, numerous derivatives have been synthetized aiming at increasing the therapeutic index.
- the antibodies according to the invention have been obtained by immunizing BALB/c mice with doxorubicin or other anthracycline compound conjugated to a suitable carrier such as bovine serum albumine by means of carbodiimide (Hurxitz e coll., Cancer Res. 35; 1175, 1975).
- the doxorubicin-carrier conjugate after emulsion in complete Freund's adjuvant, has been administered by intramuscular, subcutaneous routes in subplantar pads of inbred BALB/c mice.
- the immunization has been repeated at the l4 th 25 th , 26 th , 27 th days.
- a cellular suspension has been prepared from which red blood cells were removed by treatment with 0.17 M NH4Cl for 10′ at 4 C. 1.108 splenic cells, after washing with Hank's saline balanced solution, were placed in a test-tube together with 2x107 cells of NSl murine myeloma cells. This line of myeloma was cultured on RPMI 1640 medium containing 10% of fetal calf serum.
- the NSl and splenic cells mixture has been then treated according to the method described by Kohler e Milstein. After hybridization, the cells, re-suspended on RPMI with 20% fetal calf serum, were distributed in cell culture, 4 8 wells micro-plates (Costar, Cambridge, Mass. U.S.A.) in amount of 400.000 cell per well to which 0.3 ml of RPMI medium were added. On the subsequent day, 0.3 ml of HAT solution were added to each well. The cells were cultured for 15 days, changing the medium after 7 days.
- the surnatants of each well were then tested for the production of antibodies by immunoenzymatic test (ELISA) on the doxorubicin-carrier conjugate and on the carrier alone.
- ELISA immunoenzymatic test
- the hybridomas contained in the wells whose surnatant reacted only on the doxorubicin-carrier surnatant were cloned by serial dilutions in 96 wells-plates in the presence of peritoneal cells of BALB/c mice as nutritive medium (Feeder-layer).
- RPMI + HT medium J.W. Lifflefield, Science 145: 709-710, 1964
- fetal serum for 5 days then with RPMI and fetal serum.
- the products of the so cloned single hybridomas have been further characterized by radioisotopic binding test using as inhibitor doxorubicin itself and its analogues and derivatives, and some other chemotherapeutic agents.
- Selected hyridomas were kept in vivo in peritoneal transplant in BALB/C mice pre-treated with 2,6,10,14-tetramethylpentadecane (pristane) in order to favour the ascitis formation.
- the monoclonal antibodies obtained according to the invention may be used in the monitoring of the chemotherapeutic treatment or as histopathologic reagents for the determination of the drug in different tissues, according to usual methods.
- the monoclonal antibodies of the invention may also be used to modify the toxicity, either systemic or local, of the drug or to carry it on the target cells or to act as reagents in chemical or physical processes intended to obtain anthracyclines derivatives or complexes thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention concerns hybridomas secreting monoclonal antibodies able to selectively bind to doxorubicin as well as to analogues and derivatives thereof.
- The invention concerns also the monoclonal antibodies secreted by said hybridomas able to selectively bind to doxorubicin.
- A further object of the invention is provided by diagnostic and/or therapeutic applications of the above cited monoclonal antibodies.
- The development of the somatic hybridization technique by G. Kohler e C. Milstein (Nature, 256; 495-497, 1975) allowed the possibility of obtaining unlimited amounts of monoclonal antibodies, i.e. of antibodies having a unique and defined specificity, recognizing a single antigenic determinant.
- Said antibodies are secreted by hybrid cells, deriving from the fusion of immune lymphocytes against the desired antigen with a line of myeloma cells having specific characteristics, in order to impart immortality to the antibody producing lymphocyte cells.
- In fact, the hybrid cells deriving from said fusion, exhibit both the properties of lymphocytes of producing antibodies of a given specificity and the immortal character of the parental tumor cell.
- The hybrid cells are then cloned so as to obtain clones each deriving from a single cell, producing only one kind of antibody. The selected clone secreting the desired antibody may be kept viable undefinitely both by transplanting it in vivo in athymic mice and cultivating it in vitro.
- Thus, a monospecific reagent, able to avoid cross-reactions typical of polyspecific sera which contain, in addition to the desired reagent, numerous antibody families with different specificities, will be always available in practically unlimited amounts.
- There have been so far described monoclonal antibodies specific for different antigens of bacterial, viral, tumoral, humoral (hormones, proteins) origin, used for instance for diagnostic purpose in immunoenzymatic systems or the like, for preparative purpose, for instance for the purification of interferons, interleukins or even for therapeutic purposes, for instance in the extra-corporeal treatment of bone marrow to remove neoplastic cells or as carriers in vivo of cytotoxic agents. According to the latter aspect, the use of antitumor drugs conjugated to monoclonal antibodies directed to tumoral antigens, has been proposed.
- Very few if no example at all exist of monoclonal antibodies directed to low molecular weight compounds, poorly immunogenic, particularly of synthetic, semi-synthetic or fermentative (antibiotics) origin.
- It has now been surprisingly found that it is possible, by suitably modifying the somatic hybridisation technique according to the invention, to obtain hybridomas secreting antibodies able to selectively bind to doxorubicin as well as to analogues and derivatives.
- Doxorubicin, daunomycin and the semi-synthetic derivative epirubicin are drugs whose clinical effectiveness is widely known, belonging to the chemical class of anthracyclines; in addition to the above cited parent compounds, numerous derivatives have been synthetized aiming at increasing the therapeutic index.
- The availability of monoclonal antibodies specific to antigenic determinants of said anthracyclines compounds allow different analytic-diagnostic and/or therapeutic applications.
- The antibodies according to the invention have been obtained by immunizing BALB/c mice with doxorubicin or other anthracycline compound conjugated to a suitable carrier such as bovine serum albumine by means of carbodiimide (Hurxitz e coll., Cancer Res. 35; 1175, 1975).
- The doxorubicin-carrier conjugate, after emulsion in complete Freund's adjuvant, has been administered by intramuscular, subcutaneous routes in subplantar pads of inbred BALB/c mice.
- The immunization has been repeated at the l4th 25th, 26th, 27th days.
- For the somatic hybridization of spleens withdrawn from immune mice three days after the last boosting, a cellular suspension has been prepared from which red blood cells were removed by treatment with 0.17 M NH₄Cl for 10′ at 4 C. 1.10⁸ splenic cells, after washing with Hank's saline balanced solution, were placed in a test-tube together with 2x10⁷ cells of NSl murine myeloma cells. This line of myeloma was cultured on RPMI 1640 medium containing 10% of fetal calf serum.
- The NSl and splenic cells mixture has been then treated according to the method described by Kohler e Milstein. After hybridization, the cells, re-suspended on RPMI with 20% fetal calf serum, were distributed in cell culture, 4 8 wells micro-plates (Costar, Cambridge, Mass. U.S.A.) in amount of 400.000 cell per well to which 0.3 ml of RPMI medium were added. On the subsequent day, 0.3 ml of HAT solution were added to each well. The cells were cultured for 15 days, changing the medium after 7 days.
- The surnatants of each well were then tested for the production of antibodies by immunoenzymatic test (ELISA) on the doxorubicin-carrier conjugate and on the carrier alone. The hybridomas contained in the wells whose surnatant reacted only on the doxorubicin-carrier surnatant were cloned by serial dilutions in 96 wells-plates in the presence of peritoneal cells of BALB/c mice as nutritive medium (Feeder-layer).
- The RPMI medium added with HAT and fetal serum has been substituted with RPMI + HT medium (J.W. Lifflefield, Science 145: 709-710, 1964) and fetal serum for 5 days then with RPMI and fetal serum.
- The products of the so cloned single hybridomas have been further characterized by radioisotopic binding test using as inhibitor doxorubicin itself and its analogues and derivatives, and some other chemotherapeutic agents.
- In a series of monoclonal antibodies positive for doxorubicin, antibodies which are specifically directed to some antigenic determinants of the drug have been identified by the analysis of cross-reaction data with doxorubicin analogues, modified in one or more molecular sites.
- Selected hyridomas were kept in vivo in peritoneal transplant in BALB/C mice pre-treated with 2,6,10,14-tetramethylpentadecane (pristane) in order to favour the ascitis formation. The monoclonal antibodies obtained according to the invention may be used in the monitoring of the chemotherapeutic treatment or as histopathologic reagents for the determination of the drug in different tissues, according to usual methods.
- The monoclonal antibodies of the invention may also be used to modify the toxicity, either systemic or local, of the drug or to carry it on the target cells or to act as reagents in chemical or physical processes intended to obtain anthracyclines derivatives or complexes thereof.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT88118771T ATE103972T1 (en) | 1987-11-17 | 1988-11-11 | MONOCLONAL ANTIBODIES AGAINST ANTHRACYCLINES. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22661/87A IT1223136B (en) | 1987-11-17 | 1987-11-17 | MONOCLONAL ANTIBODIES CAPABLE OF BINDING SELECTIVELY TO DOXORUBICIN AND ANALOGS AND DERIVATIVES |
| IT2266187 | 1987-11-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0316776A2 true EP0316776A2 (en) | 1989-05-24 |
| EP0316776A3 EP0316776A3 (en) | 1991-05-22 |
| EP0316776B1 EP0316776B1 (en) | 1994-04-06 |
Family
ID=11198987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP88118771A Expired - Lifetime EP0316776B1 (en) | 1987-11-17 | 1988-11-11 | Monoclonal antibodies to anthracyclines |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5286851A (en) |
| EP (1) | EP0316776B1 (en) |
| JP (1) | JPH022394A (en) |
| AT (1) | ATE103972T1 (en) |
| DE (1) | DE3888924T2 (en) |
| ES (1) | ES2063017T3 (en) |
| IT (1) | IT1223136B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0439048A3 (en) * | 1990-01-26 | 1991-09-11 | Ist Naz Stud Cura Dei Tumori | Monoclonal antibody recognizing anthracycline glycoside specific epitope and hybridoma secerning said antibody |
| EP0503484A2 (en) * | 1991-03-12 | 1992-09-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Monoclonal antibodies as antidotes |
| WO2006104970A1 (en) * | 2005-03-30 | 2006-10-05 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020109552A1 (en) * | 2000-06-02 | 2002-08-15 | Tran Duke T. | System and method of tuning a voltage controlled oscillator |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60122372A (en) * | 1983-12-05 | 1985-06-29 | Tsunehiro Kitagawa | Reagent for quantitative determination of acralvicine |
| EP0203238A1 (en) * | 1985-01-24 | 1986-12-03 | Quidel | Apparatus for use in detecting ligands in solution |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL62965A0 (en) * | 1980-07-17 | 1981-07-31 | Scripps Miles Lab Inc | Monoclonal antibodies to drugs and theri production |
| US4517289A (en) * | 1982-08-18 | 1985-05-14 | Brigham And Women's Hospital | Monoclonal antibodies for human tissue cross-matching |
| GB8408193D0 (en) * | 1984-03-30 | 1984-05-10 | Cambridge Patent Dev | Antibodies |
-
1987
- 1987-11-17 IT IT22661/87A patent/IT1223136B/en active
-
1988
- 1988-11-11 AT AT88118771T patent/ATE103972T1/en not_active IP Right Cessation
- 1988-11-11 EP EP88118771A patent/EP0316776B1/en not_active Expired - Lifetime
- 1988-11-11 DE DE3888924T patent/DE3888924T2/en not_active Expired - Fee Related
- 1988-11-11 ES ES88118771T patent/ES2063017T3/en not_active Expired - Lifetime
- 1988-11-15 US US07/271,948 patent/US5286851A/en not_active Expired - Lifetime
- 1988-11-16 JP JP63291055A patent/JPH022394A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60122372A (en) * | 1983-12-05 | 1985-06-29 | Tsunehiro Kitagawa | Reagent for quantitative determination of acralvicine |
| EP0203238A1 (en) * | 1985-01-24 | 1986-12-03 | Quidel | Apparatus for use in detecting ligands in solution |
Non-Patent Citations (4)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 102, no. 13, 1st April 1985, page 34, abstract no. 105873q, Columbus, Ohio, US; B. LESUR et al.: "Covalent linkage of anthracyclines to macromolecular carriers", & PROTIDES BIOL. FLUIDS 1984 (PUB. 1985). 32, 437-40 * |
| INT. J. CANCER, vol. 42, 1988, pages 798-802, Alan R. Liss, Inc.; A. BALSARI et al.: "Monoclonal antibodies against doxorubicin" * |
| NATURE, vol. 256, 7th August 1975, pages 495-497; G. K\HLER et al.: "Continuous cultures of fused cells secreting antibody of predefined specificity" * |
| PATENT ABSTRACTS OF JAPAN, vol. 9, no. 281 (P-403)[2004], 8th November 1985; & JP-A-60 122 372 (TSUNEHIRO KITAGAWA) 29-06-1985 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0439048A3 (en) * | 1990-01-26 | 1991-09-11 | Ist Naz Stud Cura Dei Tumori | Monoclonal antibody recognizing anthracycline glycoside specific epitope and hybridoma secerning said antibody |
| EP0503484A2 (en) * | 1991-03-12 | 1992-09-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Monoclonal antibodies as antidotes |
| EP0503484A3 (en) * | 1991-03-12 | 1993-06-02 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Monoclonal antibodies as antidotes |
| WO2006104970A1 (en) * | 2005-03-30 | 2006-10-05 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
| US7569358B2 (en) | 2005-03-30 | 2009-08-04 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
| US8053205B2 (en) | 2005-03-30 | 2011-11-08 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
| US8084586B2 (en) | 2005-03-30 | 2011-12-27 | Saladax Biomedical, Inc. | Doxorubicin immunoassay |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2063017T3 (en) | 1995-01-01 |
| DE3888924D1 (en) | 1994-05-11 |
| US5286851A (en) | 1994-02-15 |
| IT8722661A0 (en) | 1987-11-17 |
| IT1223136B (en) | 1990-09-12 |
| EP0316776A3 (en) | 1991-05-22 |
| ATE103972T1 (en) | 1994-04-15 |
| EP0316776B1 (en) | 1994-04-06 |
| JPH022394A (en) | 1990-01-08 |
| DE3888924T2 (en) | 1994-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI91421C (en) | A method for producing a monoclonal antibody reactive with human tumor necrosis factor (TNF) and an antibody-producing hybrid cell line | |
| JP2648419B2 (en) | Monoclonal antibody mixture | |
| EP0280209B1 (en) | Monoclonal antibodies against melanoma-associated antigens, hybrid cell lines producing these antibodies, and use therefor | |
| Evans et al. | Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen | |
| CA2072249C (en) | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane | |
| CA1182406A (en) | Hybrid cell line for producing complement-fixing monoclonal antibody to human t cells, antibody, and methods | |
| FI75363C (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN MONOCLONAL ANTIKROPP MOT MAENNISKANS HJAELPAR-T-CELLER, MEDELST EN NY HYBRIDCELLINJE. | |
| JPS5845407B2 (en) | Method for producing malignant tumor antibodies | |
| FI75362B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN MONOCLONAL ANTIKROPP MOT MAENNISKANS T-CELLER, MEDELST EN NY HYBRIDCELLINJE. | |
| DK171896B1 (en) | Autologous vaccine, use of cells to produce an autologous vaccine, method of producing an autologous vaccine, method of producing a hybridoma and a cell, method of producing human monoclonal antibodies, and products obtained by these methods. | |
| JPS5859994A (en) | Recombined monoclonal antibody | |
| HU190908B (en) | Process for preparing humane-humane hybridomes and - by means thereof - monoclonal antibodies | |
| EP0038642B1 (en) | A monoclonal antibody against hepatitis b and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus b and in isolating hepatitus b surface antigen from a sample | |
| Xu et al. | Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells | |
| US5286851A (en) | Monoclonal antibodies to anthracyclines | |
| EP0156578A2 (en) | A process for preparing hybridoma cells which produce tumour specific monoclonal antibodies | |
| US4618585A (en) | Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells | |
| SAJI et al. | Monoclonal antibodies specific for two different histological types of human lung carcinoma | |
| EP0155172A2 (en) | Anti-human lung cancer monoclonal antibodies | |
| US4885358A (en) | Monoclonal antibodies specific for synthetic glycosphingolipids having abnormal branched structure | |
| SU1595902A1 (en) | Strain of mus musculus l hybrid cultivable cells for producing monoclonal antibodies to atigen cd38 | |
| RU2117043C1 (en) | Strain of cultured hybrid cells of animal mus musculus - producer of monoclonal antibodies to thermostable antigen which is common for glanders and meliodosis pathogens | |
| JPS59186923A (en) | Remedy for human prostatic cancer | |
| US5143843A (en) | Method for production of monoclonal antibodies for cancer diagnosis and therapy | |
| JP2544146B2 (en) | Nasopharyngeal cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19911028 |
|
| 17Q | First examination report despatched |
Effective date: 19920731 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| REF | Corresponds to: |
Ref document number: 103972 Country of ref document: AT Date of ref document: 19940415 Kind code of ref document: T |
|
| REF | Corresponds to: |
Ref document number: 3888924 Country of ref document: DE Date of ref document: 19940511 |
|
| ET | Fr: translation filed | ||
| ITF | It: translation for a ep patent filed | ||
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3012475 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2063017 Country of ref document: ES Kind code of ref document: T3 |
|
| EAL | Se: european patent in force in sweden |
Ref document number: 88118771.0 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051102 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20051107 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051108 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20051110 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20051116 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20051125 Year of fee payment: 18 Ref country code: CH Payment date: 20051125 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051128 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20051129 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20051201 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051230 Year of fee payment: 18 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061112 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061130 Year of fee payment: 19 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070601 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070601 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| EUG | Se: european patent has lapsed | ||
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20061111 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20070601 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070731 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061111 |
|
| BERE | Be: lapsed |
Owner name: *ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TU Effective date: 20061130 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20061113 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061113 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070604 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071111 |